Literature DB >> 12957234

R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety.

Connie Sánchez1, Piotr Gruca, Ewa Bien, Mariusz Papp.   

Abstract

S-citalopram (escitalopram) mediates the serotonin reuptake inhibitory effect of the racemate, R,S-citalopram. The effect of escitalopram (0.5-3.9 mg/kg) was investigated in a rat conditioned fear stress model of anxiety and compared to the effects of R-citalopram (1.0-7.8 mg/kg), R,S-citalopram (4.0 and 8.0 mg/kg), and escitalopram (2.0 mg/kg)+R-citalopram (7.8 mg/kg). Diazepam (0.95 mg/kg) and buspirone (4.6 mg/kg) were included as positive controls. During an acquisition session, rats were allowed to freely explore a novel cage for 9 min. During that time, they received two inescapable footshocks through an electrifiable grid floor. Groups of nonshocked control rats were run in parallel. During an expression session on the next day, rats were treated with drug or vehicle 30 min before they were reintroduced into the test cage for a 9-min period this time without receiving footshocks and the total distance travelled was recorded. The distance travelled by vehicle-treated rats was markedly suppressed compared to a vehicle-treated group of nonshocked controls. Escitalopram produced a dose-dependent inhibition of the conditioned suppression of exploratory behaviour (minimal effective dose 1.0 mg/kg). Interestingly R,S-citalopram 4.0 and 8.0 mg/kg produced significantly smaller effect than escitalopram 2.0 and 4.0 mg/kg, receptively. R-citalopram, 7.8 mg/kg, produced a significant effect. However, in spite of this, R-citalopram (7.8 mg/kg) significantly inhibited the effect of escitalopram (2.0 mg/kg). The activity in drug-treated nonshocked groups was similar to the vehicle-treated group, except for the buspirone-treated group where a significant reduction was observed. The finding that R-citalopram inhibits the effect of escitalopram may be relevant to the improved clinical efficacy seen with escitalopram compared to R,S-citalopram in the treatment of anxiety and depression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957234     DOI: 10.1016/s0091-3057(03)00165-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

1.  Specific effects of escitalopram on neuroendocrine response.

Authors:  Emily R Hawken; James A Owen; Robert W Hudson; Nicholas J Delva
Journal:  Psychopharmacology (Berl)       Date:  2009-08-07       Impact factor: 4.530

2.  In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.

Authors:  N Klein; J Sacher; T Geiss-Granadia; T Attarbaschi; N Mossaheb; R Lanzenberger; C Pötzi; A Holik; C Spindelegger; S Asenbaum; R Dudczak; J Tauscher; S Kasper
Journal:  Psychopharmacology (Berl)       Date:  2006-09-06       Impact factor: 4.530

Review 3.  Escitalopram: a review of its use in the management of anxiety disorders.

Authors:  Sohita Dhillon; Lesley J Scott; Greg L Plosker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Escitalopram effects on insula and amygdala BOLD activation during emotional processing.

Authors:  Estibaliz Arce; Alan N Simmons; Kathryn L Lovero; Murray B Stein; Martin P Paulus
Journal:  Psychopharmacology (Berl)       Date:  2007-12-06       Impact factor: 4.530

Review 5.  Escitalopram versus citalopram: the surprising role of the R-enantiomer.

Authors:  Connie Sánchez; Klaus P Bøgesø; Bjarke Ebert; Elin Heldbo Reines; Claus Braestrup
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

Review 6.  Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.

Authors:  Brian Leonard; David Taylor
Journal:  J Psychopharmacol       Date:  2010-02-10       Impact factor: 4.153

7.  Resistant social anxiety disorder response to Escitalopram.

Authors:  Stefano Pallanti; Leonardo Quercioli
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-12-13

8.  An emerging role for escitalopram in the treatment of obsessive-compulsive disorder.

Authors:  Dawson W Hedges; Fu Lye M Woon
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

9.  A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.

Authors:  Ayman Akil; Robert R Bies; Bruce G Pollock; Dimitrios Avramopoulos; D P Devanand; Jacobo E Mintzer; Anton P Porsteinsson; Lon S Schneider; Daniel Weintraub; Jerome Yesavage; David M Shade; Constantine G Lyketsos
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-26       Impact factor: 2.745

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.